This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CHIR258, CHIR-258, TKI258, TKI-258
Description: TKI258 is an orally available multi-targeted tyrosine kinase inhibitor of angiogenic growth factors, inhibiting primarily fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) receptors, but also showing inhibition of platelet-derived growth factor (PDGF) receptor, FLT3, and KIT.
Dovitinib Lactate News
Additional information available to subscribers only: